摘要
目的观察国产血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班治疗急性冠脉综合征(ACS)的近中期疗效。方法98例ACS患者分为2组,A组为常规抗ACS治疗;B组在A组的基础上加替罗非班,疗程为48 h,观察2组患者住院期间的临床疗效和实验室检查结果,并在出院后随访6～12 mo。结果2组患者的一般情况比较无明显差异,B组胸痛缓解时间明显快于A组[(41±8.3)min vs(63±11.5)min,P<0.01],7 d心血管事件发生次数少于A组(6次vs 12次,P<0.05)。B组用药后48 h内血小板计数和血小板压积明显低于A组,96 h时2组比较无明显差异。结论临床上治疗ACS时在常规治疗的基础上加用国产血小板膜糖蛋白Ⅱb/Ⅲa受体拮抗剂替罗非班能取得进一步的疗效,且安全性好。
AIM To observe the recent and intermediate stage therapy effect of domestic tirofiban on acute coronary syndromes（ACS）. METHODS Ninety-eight patients with ACS were divided into 2 groups. Group A was treated with conventional therapy; group B was treated with conventional therapy and domestic tirofiban for 48 h. The clinical effect and laboratory examination were obserced in hospital. Patients were followed up for 6 - 12 mo. RESULTS The general state condition was same in 2 groups. The relief times of angina in group B was obvious shorter than those in group A[ （41 ± 8.3） min vs （63 ± 11.5） min, P 〈 0.01], and the major adverse cardiac events in group B was lower in 7 d than in group A（ 12：6, P 〈 0.05）.The blood platelet count and thrombocytocrit were obviously lower in tirofiban group after 24 h and 48 h, but after 96 h the blood platelet count and thrombocytocrit recovered. CONCLUSION On ACS treatment the conventional therapy plus Ⅱb/Ⅲ a receptor antagonist tirofiban producted by China is effective and safe.
出处
《中国临床药学杂志》
CAS
2008年第4期200-203,共4页
Chinese Journal of Clinical Pharmacy
